Terms: = Uterine cancer AND MYH9, P35579, 4627, ENSG00000100345, DFNA17 AND Prognosis
2 results:
1. Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing myh9/GSK3β/β-catenin signaling.
Lin Y; Chen X; Lin L; Xu B; Zhu X; Lin X
Cell Mol Biol Lett; 2024 May; 29(1):63. PubMed ID: 38698330
[TBL] [Abstract] [Full Text] [Related]
2. Expression of selected molecular factors in two types of endometrial cancer.
Markowska A; Gryboś A; Marszałek A; Bednarek W; Filas V; Gryboś M; Markowska J; Mądry R; Więckowska B; Nowalińska D; Szarszewska M
Adv Clin Exp Med; 2021 Oct; 30(10):1057-1064. PubMed ID: 34510841
[TBL] [Abstract] [Full Text] [Related]
